SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics, Inc. (AMEX:CXM) announced today that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC) that, upon being declared effective by the SEC, would allow the Company to periodically sell up to $50 million of its common stock in one or more registered direct offerings. The terms of any such future offerings will be established at the time of an offering. The shelf registration enables the Company to take advantage of favorable market conditions as they arise and to complement funding from potential corporate collaborations and other sources of revenue. Proceeds from the sale of any common stock will be used for the purposes described in the prospectus or prospectus supplement filed at the time of an offering.
